DOCSLIB.ORG

50 Years of INRC: 1969 to 2019 – 55 Years of Our Rockefeller University Research and 50 to 60 Years of Opioid Research Mary Jeanne Kreek, M.D

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
50 Years of INRC: 1969 to 2019 – 55 Years of Our Rockefeller University Research and 50 to 60 Years of Opioid Research Mary Jeanne Kreek, M.D 50 Years of INRC: 1969 to 2019 – 55 Years of our Rockefeller University Research and 50 to 60 Years of Opioid Research Mary Jeanne Kreek, M.D. Patrick E. and Beatrice M. Haggerty Professor Head of Laboratory The Laboratory of the Biology of Addictive Diseases The Rockefeller University Senior Physician, The Rockefeller University Hospital International Narcotics Research Conference July 8, 2019 New York, NY Funded primarily by Dr. Miriam and Sheldon Adelson Medical Research Foundation, NIH-NIDA, NIH-NIAAA, NIH-CRR, Tri-Institutional Therapeutics Discovery Institute, Robertson Therapeutic Development Fund, and others International Narcotics Research Conference Founders Lecturers (First Awardee 1999) 1999 Eric J. Simon 2009 R. Alan North 2000 Brian M. Cox 2010 Masamichi Satoh 2001 Philip S. Portoghese 2011 Charles Chavkin 2002 Lars Terenius 2012 F. Ivy Carroll 2003 Bernard Roques 2013 Graeme Henderson 2004 Ji-Sheng Han 2014 Christopher Evans 2005 Mary Jeanne Kreek Brigitte Kieffer 2006 Huda Akil 2015 Gavril Pasternak (d. 2019) Stan Watson 2016 Lakshmi Devi 2007 Volker Hoellt 2017 John Traynor Horace Loh 2018 Macdonald Christie 2008 Jan van Ree 2019 Sol Snyder Kreek 2019 International Narcotics Research Conference Founders Lecturers at this 50th Anniversary Meeting 1999 Eric J. Simon 2009 R. Alan North 2000 Brian M. Cox 2010 Masamichi Satoh 2001 Philip S. Portoghese 2011 Charles Chavkin 2002 Lars Terenius 2012 F. Ivy Carroll 2003 Bernard Roques 2013 Graeme Henderson 2004 Ji-Sheng Han 2014 Christopher Evans 2005 Mary Jeanne Kreek Brigitte Kieffer 2006 Huda Akil 2015 Gavril Pasternak (d. 2019) Stan Watson 2016 Lakshmi Devi 2007 Volker Hoellt 2017 John Traynor Horace Loh 2018 Macdonald Christie 2008 Jan van Ree 2019 Sol Snyder Kreek 2019 Ji-Sheng Han cannot attend this 50th Anniversary meeting because of a family illness and sends his regards, along with this photo of him with his family. Ivy Carroll and Bernard Roques are unable to attend this year because of illness. Brigitte Kieffer and Huda Akil could not attend because of university business. All send their regards! Kreek 2019 Early Opioid Research of Martin (US) and Collier (UK) – 1961 Hypothesis and experimental evidence of the development of tolerance to and dependence on opiates with chronic exposure (heroin, morphine, methadone, other) Martin, W.R., Frasier, H.F. A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in postaddicts. JPET, 133:388-99. (1961) Collier, H.O., Warner, B.T., Skerry, R. Multiple toe-pinch method for testing analgesic drugs. Br J Pharmacol Chemother. 17:28-40. (1961) (in rodents) Frasier, H.F., Van Horn, G.D., Martin, W.R., Wolbach, A.B., Isbell, H. Methods for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-like drugs. (B) a short-term “direct” addiction test. JPET, 133:371-87. (1961) Martin, W.R., Eades, C.G. Demonstration of tolerance and physical dependence in the dog following short-term infusion of morphine. JPET, 133:262-70. (1961) Kreek 2019 55th Anniversary of the Beginning of Our Rockefeller Institute (now University) Research: 1963-1964 Treatment of Heroin Addiction: Identification of Need, Formulation of Hypothesis, Basic Clinical and Related Laboratory Research, Translational Research, and Evaluations Autumn Vincent P. Dole, Jr., MD recruitment of two new staff 1963 members to his Laboratory of Physiology and Metabolism at The Rockefeller Institute for Medical Research: 1) Marie Nyswander, MD – psychiatrist, years of work with heroin addicts in New York City and Lexington, KY. Author of book The Addict as a Patient. 2) Mary Jeanne Kreek, MD – second year Resident in (Internal) Medicine (“PGY-2”) at Cornell-New York Hospital with experience in clinical and laboratory based research at NIH and Columbia P&S. January – New team formed and first patients admitted to the July 1964 Rockefeller Hospital; initial research on potential novel pharmacological treatment of heroin addiction, accomplished by July 1964. Kreek 2019 Development of Methadone Maintenance Treatment – 1964-1966 1964 HYPOTHESIS –NOW EVIDENCE-BASED FACT: Heroin (opiate) addiction is a disease – a “metabolic disease” – of the brain with resultant behaviors of “drug hunger” and drug self-administration, despite negative consequences to self and others. Heroin addiction is not simply a criminal behavior or due alone to antisocial personality or some other personality disorder. First publications describing methadone maintenance treatment research 1) 1964: Initial clinical research on development of treatment using methadone maintenance pharmacotherapy and on elucidating mechanisms of efficacy performed at The Rockefeller Hospital of The Rockefeller Institute for Medical Research: Dole, V.P., Nyswander, M.E. and Kreek, M.J.: Narcotic blockade. Arch. Intern. Med., 118:304-309, 1966. (also recorded in the Association of American Physicians meeting transcription of discussion) 2) 1965: Translational applied clinical research performed at Manhattan General Hospital: Dole, V.P. and Nyswander, M.E.: A medical treatment for diacetylmorphine (heroin) addiction. JAMA, 193:646-650, 1965. Kreek 2019 Impact of Short-Acting Heroin versus Long-Acting Methadone Administered on a Chronic Basis in Humans (1964 through 1973 Studies): Opioid Agonist Pharmacokinetics – Heroin Versus Methadone “On-Off” Apparent Plasma Terminal "High" Drug or Half-life and Duration of Medication Desired Effects HEROIN 3 min for prodrug "Straight" 30 min for active (Heroin) "Sick" compound, mono-acetyl morphine (fast on-set and Functional Functional State AM PM AM PM AM off-set) Days “Steady State” 6 hours for active metabolites (morphine "High" and others) METHADONE 24h for racemic (rs) "Straight" medication (slow on-set and off-set – steady-state (Methadone) achieved) Functional Functional State "Sick" 48h for active (r) AM PM AM PM AM enantiomer Days H Dole, Nyswander and Kreek, 1966; Kreek et al., 1973; 2019 1973 Kreek, New York State Journal of Medicine, Vol. 73, No. 23, December 1, 1973 “On-Off” versus “Steady-State”: Relationship Between Blood (and Brain) Levels of Drugs of Abuse and Their Effects Disruption versus Normalization • levels of gene expression • receptor mediated events • physiology • behaviors Rates of rise of blood (and presumable brain) levels of drugs of abuse are related positively to their reinforcing effects Rates of fall of blood (and presumably brain) levels of drugs of abuse are related positively to the onset of withdrawal symptoms and/or acute “craving” Kreek, 1973 on, 2019 1965-1968: Early Expansion of Methadone Maintenance Treatment 1964-1967 – Initially all patients admitted as active or recently abstinent heroin addicts to the Rockefeller Hospital, unlocked research ward for inpatient induction into methadone maintenance treatment (minimum 6- 8 weeks). Follow-up in Rockefeller Hospital Outpatient Department. 1965-1966 – Replication of methadone maintenance treatment research model in an inpatient unit of the Manhattan General Hospital, a fee-for- service proprietary hospital (later to become the Bernstein Institute of Beth Israel Hospital), which had been engaged in 10-14 day detoxification “treatment” for opiates (“revolving door”). 1967-1968 – Introduction of outpatient induction into methadone maintenance treatment (at the Rockefeller Hospital clinic, Dr. MJ Kreek). Kreek 2019 Prospective studies of first 214 patients admitted to methadone maintenance research and treatment (January 1964 – July 1966, and followed-up for three years or more) and Retrospective Study of 1435 methadone maintenance patients. 1973 1967-1973: Further Expansion of Methadone Maintenance Treatment and FDA Approval 1967-1972 – Development of multiple satellite outpatient methadone maintenance treatment programs at Harlem, Beth Israel, St. Luke’s, Roosevelt, and Einstein Hospitals in New York City (Dole, Nyswander, Kreek, Lowinson, et al.). 1967-1972 – First replication of methadone maintenance program outside of New York City – Department of Psychiatry, University of Uppsala, Uppsala, Sweden (Dr. Lars Gunne and later Drs. Leif Grönbladh and Olof Blix). 1969-1973 – Opening of the “Adolescent Development Program” (self- administration for > three years in age 15-21) (Elizabeth Khuri and Robert Millman) and “Adult Program” (Aaron Wells) at New York Hospital- Cornell Medical Center. 1973 – Approval by US-FDA of long-term moderate to high dose methadone maintenance treatment for opiate addiction. Kreek 2019 Synthesis and Early Studies of Mu Opioid Receptor Antagonists Naloxone, and Subsequently Naltrexone and Nalmefene: Use in Reversal of Opiate Overdose and Later Treatment of Addictive Diseases (1967 onward) In 1967, Dr. Jack Fishman, a chemist and endocrinologist working with several institutions in New York City, visited with one of his former medical students (MJK) for lunch at The Rockefeller University. At that lunch, he shared that he had synthesized a new compound hoping that it would be a “non-addicting pain medication,” but in fact it did not relieve pain, instead it reversed the effect of short-acting opiate agonists such as heroin and morphine. “Would there be a clinical use for such a compound?” (JF) That compound was naloxone (Narcan™), which is now used world over for the reversal of opiate overdose, as well as planned narcotic effects during surgery and related procedures. Dr. Fishman also synthesized and assisted in the development of nalmefene and naltrexone. Naltrexone was studied and subsequently FDA
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • The Critical Importance of Basic Animal Research for Neuropsychiatric Disorders
    The critical importance of basic animal research for neuropsychiatric disorders Tracy L. Bale1, Ted Abel2, Huda Akil3, William A. Carlezon4, Bita Moghaddam5, Eric J. Nestler6, Kerry J. Ressler7 and Scott M. Thompson8 1 Center for Epigenetic Research in Child Health and Brain Development, Departments of Pharmacology and Psychiatry, University of Maryland School of Medicine, Baltimore, MD, [email protected] 2 Department of Pharmacology and Iowa Neuroscience Institute, Carver College of Medicine, University of Iowa, Iowa City, IA, [email protected] 3 Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, [email protected] 4 McLean Hospital, Department of Psychiatry, Harvard School of Medicine, Belmont, MA, [email protected] 5 Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, OR, [email protected] 6 Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, [email protected] 7 McLean Hospital, Department of Psychiatry, Harvard School of Medicine, Belmont, MA, [email protected] 8 Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, [email protected] Contact information: Tracy L. Bale, Ph.D. Professor and Director, Center for Epigenetic Research in Child Health and Brain Development Departments of Pharmacology and Psychiatry University of Maryland School of Medicine, Baltimore, MD 21201 [email protected] ph 410-706-5816 Acknowledgements: Authors acknowledge support funding from NIMH grants: MH104184, MH108286, MH099910 (TLB); MH086828 (SMT); MH048404, MH115027 (BM), MH063266 (WAC), MH108665, MH110441, MH110925, MH117292 (KJR); MH051399, MH096890 (EJN), MH104261 (HA), MH087463, MH117964 (TA). The challenges and critical importance of keeping our thinking about neuropsychiatric disorders mechanisms and classifications up-to-date have prompted a dynamic discourse as to the value, appropriateness, and reliability of the animal models we use and the outcomes we measure.
    [Show full text]
  • Uneven Balance of Power Between Hypothalamic Peptidergic Neurons in the Control of Feeding
    Uneven balance of power between hypothalamic peptidergic neurons in the control of feeding Qiang Weia, David M. Krolewskia, Shannon Moorea, Vivek Kumara, Fei Lia, Brian Martina, Raju Tomerb, Geoffrey G. Murphya, Karl Deisserothc, Stanley J. Watson Jr.a, and Huda Akila,1 aMolecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109; bDepartment of Biological Sciences, Columbia University, New York, NY 10027; and cDepartment of Bioengineering, Stanford University, Stanford, CA 94305 Contributed by Huda Akil, August 7, 2018 (sent for review February 6, 2018; reviewed by Olivier Civelli and Allen Stuart Levine) Two classes of peptide-producing neurons in the arcuate nucleus consumption, while anorexigenic neurons that express POMC in- (Arc) of the hypothalamus are known to exert opposing actions on hibit feeding behavior. AgRP/NPY neurons are active when the feeding: the anorexigenic neurons that express proopiomelano- energy stores are not sufficient to meet systemic demands, thereby cortin (POMC) and the orexigenic neurons that express agouti- releasing AgRP and promoting feeding (9, 10). POMC is a complex related protein (AgRP) and neuropeptide Y (NPY). These neurons polypeptide precursor cleaved into active peptides including mel- are thought to arise from a common embryonic progenitor, but anocortins and β-endorphin (11). While β-endorphin is a long- our anatomical and functional understanding of the interplay of acting opioid analgesic (12), the cosynthesized α-melanocyte stim- these two peptidergic systems that contribute to the control of ulating hormone (α-MSH) blocks appetite (13). These two sets of feeding remains incomplete. The present study uses a combination peptidergic neurons in the Arc respond to nutrient and hormonal of optogenetic stimulation with viral and transgenic approaches, signals from the periphery.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Distinct Mu, Delta, and Kappa Opioid Receptor Mechanisms Underlie Low Sociability and Depressive-Like Behaviors During Heroin Abstinence
    Neuropsychopharmacology (2014) 39, 2694–2705 & 2014 American College of Neuropsychopharmacology. All rights reserved 0893-133X/14 www.neuropsychopharmacology.org Distinct Mu, Delta, and Kappa Opioid Receptor Mechanisms Underlie Low Sociability and Depressive-Like Behaviors During Heroin Abstinence ,1,2 1 1 1 1 Pierre-Eric Lutz* , Gulebru Ayranci , Paul Chu-Sin-Chung , Audrey Matifas , Pascale Koebel , 1 1 1 ,1,3 Dominique Filliol , Katia Befort , Abdel-Mouttalib Ouagazzal and Brigitte L Kieffer* 1Translational Medicine and Neurogenetics, Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire, INSERM U-964, CNRS UMR-7104, 2 Universite´ de Strasbourg, Illkirch, France; McGill Group for Suicide Studies, Douglas Institute Research Centre, McGill University, Montre´al, 3 Que´bec, Canada; Douglas Institute Research Centre, McGill University, Montre´al, Que´bec, Canada Addiction is a chronic disorder involving recurring intoxication, withdrawal, and craving episodes. Escaping this vicious cycle requires maintenance of abstinence for extended periods of time and is a true challenge for addicted individuals. The emergence of depressive symptoms, including social withdrawal, is considered a main cause for relapse, but underlying mechanisms are poorly understood. Here we establish a mouse model of protracted abstinence to heroin, a major abused opiate, where both emotional and working memory deficits unfold. We show that delta and kappa opioid receptor (DOR and KOR, respectively) knockout mice develop either stronger or reduced emotional disruption during heroin abstinence, establishing DOR and KOR activities as protective and vulnerability factors, respectively, that regulate the severity of abstinence. Further, we found that chronic treatment with the antidepressant drug fluoxetine prevents emergence of low sociability, with no impact on the working memory deficit, implicating serotonergic mechanisms predominantly in emotional aspects of abstinence symptoms.
    [Show full text]
  • Huda Akil, Ph.D
    Huda Akil, Ph.D. is the Gardner Quarton Distinguished University Professor of Neuroscience and Psychiatry and the co-Director of the Molecular & Behavioral Neuroscience Institute (MBNI) at the University of Michigan. Dr. Akil and her colleagues have made seminal contributions to the understanding of the brain biology of emotions, including pain, stress, anxiety and substance abuse. Her current research investigates the genetic and neural mechanisms underlying addiction and mood disorders. Among her contributions, Dr. Akil provided the first physiological evidence for a role of endorphins in the brain, and showed that endorphins are activated by stress and cause pain inhibition. Her laboratory has developed new genetic animal models of temperament and shown their relevance to human disorders, including addiction and depression. She is a member of the Pritzker Consortium, which is engaged in large-scale studies to discover new genes and proteins that cause vulnerability to major depression and bipolar illness. Her work has uncovered the role of the Fibroblast Growth Factor (FGF) family in depression, anxiety and established its functions in the development and control of emotions. Dr. Akil has served on several national and international organizations to promote scientific and brain health awareness nationally and globally. She is the past President of the American College of Neuropsychopharmacology (1998) and the past President of the Society for Neuroscience (2004) the largest neuroscience organization in the world. She has served two terms on the Council of the National Academy of Medicine and served on the National Research Council (NRC) review board. Dr. Akil’s contributions have been recognized with numerous honors and awards, including honorary doctorates.
    [Show full text]
  • WAVE1 in Neurons Expressing the D1 Dopamine Receptor Regulates Cellular and Behavioral Actions of Cocaine
    WAVE1 in neurons expressing the D1 dopamine receptor regulates cellular and behavioral actions of cocaine Ilaria Cegliaa,1, Ko-Woon Leea,1, Michael E. Cahillb,1, Steven M. Gravesc, David Dietzd, Dalton J. Surmeierc, Eric J. Nestlerb, Angus C. Nairna,e, Paul Greengarda,2, and Yong Kima,2 aLaboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065; bFishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029; cDepartment of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611; dDepartment of Pharmacology and Toxicology, Research Institute on Addictions, Program in Neuroscience, State University of New York at Buffalo, Buffalo, NY 14214; and eDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT 06508 Contributed by Paul Greengard, December 23, 2016 (sent for review October 26, 2016; reviewed by Huda Akil and Solomon H. Snyder) Wiskott-Aldrich syndrome protein (WASP) family verprolin homolo- upon stimulation of D1 dopamine and of NMDA glutamate re- + gous protein 1 (WAVE1) regulates actin-related protein 2/3 (Arp2/3) ceptors, acting through cAMP- and Ca2 -mediated activation of complex-mediated actin polymerization. Our previous studies have protein phosphatase 2A and 2B, respectively (4, 7). These results found WAVE1 to be inhibited by Cdk5-mediated phosphorylation indicate that WAVE1 is a neuronal activity-regulated phospho- in brain and to play a role in the regulation of dendritic spine mor- protein in the striatum. phology. Here we report that mice in which WAVE1 was knocked out We previously identified a pivotal role for Cdk5/p35 in cocaine- (KO) in neurons expressing the D1 dopamine receptor (D1-KO), but induced adaptive changes in brain (8).
    [Show full text]
  • Co-Regulation of Hormone Receptors, Neuropeptides, and Steroidogenic Enzymes 2 Across the Vertebrate Social Behavior Network 3 4 Brent M
    bioRxiv preprint doi: https://doi.org/10.1101/435024; this version posted October 4, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Co-regulation of hormone receptors, neuropeptides, and steroidogenic enzymes 2 across the vertebrate social behavior network 3 4 Brent M. Horton1, T. Brandt Ryder2, Ignacio T. Moore3, Christopher N. 5 Balakrishnan4,* 6 1Millersville University, Department of Biology 7 2Smithsonian Conservation Biology Institute, Migratory Bird Center 8 3Virginia Tech, Department of Biological Sciences 9 4East Carolina University, Department of Biology 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 bioRxiv preprint doi: https://doi.org/10.1101/435024; this version posted October 4, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Running Title: Gene expression in the social behavior network 2 Keywords: dominance, systems biology, songbird, territoriality, genome 3 Corresponding Author: 4 Christopher Balakrishnan 5 East Carolina University 6 Department of Biology 7 Howell Science Complex 8 Greenville, NC, USA 27858 9 [email protected] 10 2 bioRxiv preprint doi: https://doi.org/10.1101/435024; this version posted October 4, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Interplay Between Peripheral Signals, Behaviour and the Central Clock
    Interplay between peripheral signals, behaviour and the central clock Claire Gizowski Integrated Program in Neuroscience, McGill University October 2019 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy © Claire Gizowski 2019 TABLE OF CONTENTS SECTION PAGE ABSTRACT ................................................................................................................................... 3 ACKNOWLEDGMENTS ............................................................................................................. 5 PEER-REVIEWED PUBLICATIONS ARISING FROM THIS WORK ............................... 6 CONTRIBUTION TO ORIGINAL KNOWLEDGE ................................................................. 7 CONTRIBUTION OF AUTHORS .............................................................................................. 9 LIST OF ABBREVIATIONS ..................................................................................................... 10 CHAPTERS .................................................................................................................................... CHAPTER 1 – Introduction ............................................................................................. 13 CHAPTER 1.0 – Foreword ................................................................................. 13 CHAPTER 1.1 – General introduction ............................................................... 13 CHAPTER 1.1.1 –The clock ..............................................................................
    [Show full text]
  • Dr Michael Bruchas Michael Bruchas’S Research Training Is in GPCR Pharmacology and Neuroscience
    INRC 2014 Awardees Dr Brigitte Kieffer B. L. Kieffer is Professor at McGill Univerity and at the Université de Strasbourg France. Her team uses mouse genetic approaches to tacKle the role of opioid receptors in brain physiology and disorders, and to search for novel genes involved in psychiatric disorders. She has developed and shared exquisite genetic tools worldwide, and has developed innovative research lines with strong impact in neuroscience and biomedical research. Her worK has important implications for the development of treatment of pain, drug abuse and emotional disorders. She is part of the Center for Opioid Receptors and Drugs of Abuse or CSORDA. Pr. Kieffer is recipient of the Jules Martin (French Academy of Science, 2001) and the Lounsbery (French and US Academies of Science, 2004) Awards, and has become an EMBO Member in 2009. In 2012 she received the Lamonica Award of Neurology (French Academy of Science) and was nominated Chevalier de la Légion lecture d’honneur. In December 2013 she was elected as a member of the French Academy of Sciences. She started as the Scientific Director of the Douglas Hospital Research Centre, affiliated to McGill University in January 2014. Dr Christopher Evans Christopher Evans received his Ph.D. from Imperial College London, conducting his Founder’s thesis research on endorphins and enkephalins, at the Medical Research Council Institute in Mill Hill. After a postdoctoral fellowship at Stanford University, he joined the UCLA faculty in the Department of Psychiatry and Biobehavioral Science. His research accomplishments have included identification of a number of novel endogenous opioid peptides and the cloning of the first opioid receptor.
    [Show full text]
  • Role of Mu-Opioid Receptors in the Behavioral Effects of the Antidepressant
    Role of Mu-Opioid Receptors in the Behavioral Effects of the Antidepressant Tianeptine Jaena Han Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2021 © 2021 Jaena Han All Rights Reserved Abstract Role of Mu-Opioid Receptors in the Behavioral Effects of the Antidepressant Tianeptine Jaena Han For over half a century, the monoamine hypothesis has been the dominant theoretical framework guiding depression research and drug development. This hypothesis posits that depression arises from a deficiency in the monoaminergic neurotransmitters serotonin, norepinephrine, and possibly dopamine, and that antidepressants function by increasing extracellular availability of these monoamines in the brain, especially at the synaptic level. It is clear however, that the monoamine hypothesis cannot fully explain either the pathophysiology of depression nor the mechanisms of antidepressant action. Tianeptine is an atypical antidepressant used in Europe to treat patients who respond poorly to selective serotonin reuptake inhibitors (SSRIs). The recent discovery that tianeptine is a mu opioid receptor (MOR) and delta opioid receptor (DOR) agonist has provided a potential avenue for expanding our understanding of antidepressant treatment beyond the monoamine hypothesis. This dissertation aims to understand the neural circuits underlying tianeptine’s antidepressant effects. We first characterized the acute and chronic effects of tianeptine on depressive-like and other opioid-related behaviors in mice, and used genetic and pharmacological models to test whether these behavioral effects are mediated by MOR and/or DOR. We found that acute tianeptine administration produced an antidepressant-like reduction in immobility time in the forced swim test, as well as classic opioid-like effects including analgesia, hypophagia, hyperactivity, and conditioned place preference.
    [Show full text]
  • Localization of Dopamine D, Receptor Mrna and D, and D, Receptor Binding in the Rat Brain and Pituitary: an in Situ Hybridization-Receptor Autoradiographic Analysis
    The Journal of Neuroscience, August 1990, 70(8): 2587-2800 Localization of Dopamine D, Receptor mRNA and D, and D, Receptor Binding in the Rat Brain and Pituitary: An in situ Hybridization-Receptor Autoradiographic Analysis Alfred Mansour,’ James H. Meador-Woodruff,i James R. Bunzow,2 Olivier Civelli,* Huda Akil,’ and Stanley J. Watson’ ‘Mental Health Research Institute, University of Michigan, Ann Arbor, Michigan 48109-0720, and *Vellum Institute for Advanced Biomedical Research, The Oregon Health Sciences University, Portland, Oregon 97201 Several lines of evidence suggest the existence of multiple Cumulative evidence suggeststhe existence of at least 2 distinct dopamine receptor subtypes, referred to as D, and D,. The dopaminergic receptor subtypes, referred to as D, and D,. D, present study examines the distribution of these dopamine dopamine (DA) receptors are positively coupled to adenylate binding sites in the rat brain and pituitary in relation to the cyclase (Stoof and Kebabian, 1984), widely distributed in the distribution of D, receptor mRNA using a combination of in CNS (Boyson et al., 1986; Dawson et al., 1986; Dubois et al., vitro receptor autoradiographic and in situ hybridization 1986; Bouthenet et al., 1987; Wamsley et al., 1989), and abun- techniques. 3H-Raclopride and 3H-SCH23390 (in the pres- dant in the parathyroid gland (Attie et al., 1980). D, DA recep- ence of 1 ELM ketanserin) were used to label D, and D, re- tors, on the other hand, are either not coupled to adenylate ceptor binding sites, respectively, while a 495 bp cRNA probe cyclase (Memo et al., 1986) or negatively coupled (Onali et al., synthesized from the Sac I-Bglllfragment of a rat D, receptor 1985) and are densely distributed in the basal ganglia (Martres cDNA was used to visualize the D, receptor mRNA.
    [Show full text]